LU AF28996 DH1 is an experimental oral capsule that is being studied to see if it can help adults with Parkinson’s disease who have motor fluctuations. In this trial, participants take the capsule by mouth, and researchers will compare how well it works at reducing motor complications compared with a placebo. The study is designed to be double‑blind, meaning neither the participants nor the doctors know who receives the active capsule, which helps ensure the results are reliable. The goal is to determine whether this new medication can improve the control of movement problems in people with Parkinson’s disease.

Parkinson’s disease – Parkinson’s disease is a brain disorder that mainly affects movement. It develops when nerve cells that produce dopamine gradually die, leading to reduced dopamine levels. Early signs often include slight tremor, stiffness, or slower movements. Over time, symptoms can spread to cause difficulty walking, balance problems, and facial expression changes. Many people also experience non‑motor symptoms such as sleep disturbances, mood changes, and decreased sense of smell as the condition advances. The disease typically progresses slowly, with symptoms becoming more noticeable and widespread over several years.